Clinical trials: Hair Loss
Alopecia
Hair Loss Prevention Study for Pancreatic Cancer
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
- Trial name
- NCT04492800
- Testing
- Paxman Scalp Cooling Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- HonorHealth Research Institute
Alopecia
Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.
- Trial name
- NCT03488108
- Testing
- Platelet Rich Plasma, Minoxidil Foam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Male Pattern Hair Loss, Androgenetic Alopecia
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of…
- Trial name
- NCT02170662
- Testing
- Bimatoprost
- Volunteers
- 33 people
- Sponsor
- Duke University
Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called…
- Trial name
- NCT05650333
- Testing
- Ritlecitinib 20 mg
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Alopecia Areata
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
- Trial name
- NCT04784533
- Testing
- CTP-543
- Where
- 39 sites in United States
- Volunteers
- 317 people
- Sponsor
- Concert Pharmaceuticals
Alopecia Areata
LEO 124249 Ointment in the Treatment of Alopecia Areata
This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.
- Trial name
- NCT02561585
- Testing
- LEO 124249, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Central Centrifugal Cicatricial Alopecia
A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
The purpose of this study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for Central centrifugal cicatricial alopecia (CCCA) by recruiting hair follicles back to anagen growth or by…
- Trial name
- NCT05759338
- Testing
- Revian Red All LED cap
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Alopecia
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of 0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia types III vertex, IV and V per the…
- Trial name
- NCT01831791
- Testing
- Dutasteride 0.5 mg
- Where
- 5 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Alopecia Areata
Healthcare Disparities in Alopecia Areata
Alopecia areata (AA) is a common immune-mediated non-scarring alopecia often associated with substantial morbidity. There are however, limited population-based data on potential disparities in the burden of AA, including across…
- Trial name
- NCT05727306
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 4,052,231 people
- Sponsor
- Momentum Data
Actinic Keratosis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp.
- Trial name
- NCT01686152
- Testing
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Where
- 23 sites in United States
- Volunteers
- 589 people
- Sponsor
- Teva Pharmaceuticals USA
Cicatricial Alopecia
Ritlecitinib for Cicatricial Alopecia
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known…
- Trial name
- NCT05549934
- Testing
- PF-06651600
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Emma Guttman
Androgenetic Alopecia
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic…
- Trial name
- NCT02503137
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Biosplice Therapeutics, Inc.
Alopecia Areata
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks.
- Trial name
- NCT02974868
- Testing
- PF-06651600, PF-06700841
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 142 people
- Sponsor
- Pfizer
Alopecia Areata
Intralesional Steroids in the Treatment of Alopecia Areata
This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo…
- Trial name
- NCT01898806
- Testing
- Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Multiple Myeloma
Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
This pilot study of scalp cooling with Penguin cold caps will examine the effectiveness of scalp cooling to reduce the development of hair loss in 30 participants with multiple myeloma undergoing high-dose chemotherapy with…
- Trial name
- NCT05961215
- Testing
- Penguin Cold Cap
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Cedars-Sinai Medical Center
Alopecia Areata
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
- Trial name
- Allegro2a (NCT04517864)
- Testing
- PF-06651600
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Alopecia Areata
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).
- Trial name
- NCT04556734
- Testing
- Etrasimod
- Where
- 42 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Pfizer
Alopecia Areata, Alopecia Totalis
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT02312882
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Androgenetic Alopecia, Alopecia
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
The purpose of this study is to evaluate the clinical efficacy of platelet rich plasma (PRP) injections for non-scaring alopecia in women.
- Trial name
- NCT03689452
- Testing
- Platelet Rich Plasma, Normal saline
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cicatricial Alopecia
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known…
- Trial name
- NCT05076006
- Testing
- PF-06700841
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Emma Guttman